| 2.07 -0.05 (-2.36%) | 06-18 10:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.64 | 1-year : | 27.09 |
| Resists | First : | 15.1 | Second : | 23.2 |
| Pivot price | 2.35  |
|||
| Supports | First : | 2 | Second : | 1.67 |
| MAs | MA(5) : | 2.16 |
MA(20) : | 2.84 |
| MA(100) : | 8.97 |
MA(250) : | 12.59 |
|
| MACD | MACD : | -1.3  |
Signal : | -1.5 |
| %K %D | K(14,3) : | 5.7 |
D(3) : | 6.8 |
| RSI | RSI(14): 29.8 |
|||
| 52-week | High : | 24.29 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SBFM ] has closed above bottom band by 11.8%. Bollinger Bands are 74.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.17 - 2.19 | 2.19 - 2.2 |
| Low: | 2.03 - 2.05 | 2.05 - 2.06 |
| Close: | 2.1 - 2.12 | 2.12 - 2.14 |
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 144 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -12.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 43.83 |
| Profit Margin | -17.1 % |
| Operating Margin | -17.3 % |
| Return on Assets (ttm) | -10.1 % |
| Return on Equity (ttm) | -27.4 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 5.52 |
| Sales Per Share | 16.74 |
| EBITDA (p.s.) | -2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | 0.04 |
| Price to Sales | 0.12 |
| Price to Cash Flow | -0.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|